These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3005212)

  • 1. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties.
    Goetz MA; Lopez M; Monaghan RL; Chang RS; Lotti VJ; Chen TB
    J Antibiot (Tokyo); 1985 Dec; 38(12):1633-7. PubMed ID: 3005212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus.
    Chang RS; Lotti VJ; Monaghan RL; Birnbaum J; Stapley EO; Goetz MA; Albers-Schönberg G; Patchett AA; Liesch JM; Hensens OD
    Science; 1985 Oct; 230(4722):177-9. PubMed ID: 2994227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation.
    Liesch JM; Hensens OD; Springer JP; Chang RS; Lotti VJ
    J Antibiot (Tokyo); 1985 Dec; 38(12):1638-41. PubMed ID: 3841533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel cholecystokinin antagonists from Aspergillus alliaceus. I. Fermentation, isolation, and biological properties.
    Goetz MA; Monaghan RL; Chang RS; Ondeyka J; Chen TB; Lotti VJ
    J Antibiot (Tokyo); 1988 Jul; 41(7):875-7. PubMed ID: 3417561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the biosynthesis of asperlicin and the directed biosynthesis of analogs in Aspergillus alliaceus.
    Houck DR; Ondeyka J; Zink DL; Inamine E; Goetz MA; Hensens OD
    J Antibiot (Tokyo); 1988 Jul; 41(7):882-91. PubMed ID: 3417563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asperlicin antagonizes stimulatory effects of cholecystokinin on isolated islets.
    Zawalich WS; Diaz VA
    Am J Physiol; 1987 Mar; 252(3 Pt 1):E370-4. PubMed ID: 3548432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.
    Bock MG; DiPardo RM; Rittle KE; Evans BE; Freidinger RM; Veber DF; Chang RS; Chen TB; Keegan ME; Lotti VJ
    J Med Chem; 1986 Oct; 29(10):1941-5. PubMed ID: 3761313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists.
    Lattmann E; Billington DC; Poyner DR; Howitt SB; Offel M
    Drug Des Discov; 2001; 17(3):219-30. PubMed ID: 11469752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
    Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
    Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cholecystokinin antagonists from Aspergillus alliaceus. II. Structure determination of asperlicins B, C, D, and E.
    Liesch JM; Hensens OD; Zink DL; Goetz MA
    J Antibiot (Tokyo); 1988 Jul; 41(7):878-81. PubMed ID: 3417562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.
    Evans BE
    Z Gastroenterol Verh; 1991 Mar; 26():269-71. PubMed ID: 1714170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
    Chang RS; Lotti VJ
    Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that cholecystokinin octapeptide (CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in the isolated mouse stomach: lack of antagonism by the specific CCK antagonist asperlicin.
    Lotti VJ; Chang RS; Kling PJ; Cerino DJ
    Digestion; 1986; 35(3):170-4. PubMed ID: 3781112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists.
    Van der Bent A; Ter Laak AM; IJzerman AP; Soudijn W
    Eur J Pharmacol; 1992 Aug; 226(4):327-34. PubMed ID: 1397061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
    Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Gould NP; Lundell GF; Homnick CF; Veber DF
    J Med Chem; 1987 Jul; 30(7):1229-39. PubMed ID: 2885419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin receptor antagonists.
    Zucker KA; Adrian TE; Modlin IM
    J Surg Res; 1988 Nov; 45(5):496-504. PubMed ID: 3054325
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of metoclopramide, bethanechol and the cholecystokinin receptor antagonist, L-364,718, on gastric emptying in the rat.
    Decktor DL; Pendleton RG; Elnitsky AT; Jenkins AM; McDowell AP
    Eur J Pharmacol; 1988 Mar; 147(2):313-6. PubMed ID: 3366182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
    Kerwin JF; Nadzan AM; Kopecka H; Lin CW; Miller T; Witte D; Burt S
    J Med Chem; 1989 Apr; 32(4):739-42. PubMed ID: 2704023
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS; Lotti VJ; Chen TB; Kunkel KA
    Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised NMR assignments for the cholecystokinin antagonist asperlicin.
    Sun HH; Byard SJ; Cooper R
    J Antibiot (Tokyo); 1994 May; 47(5):599-601. PubMed ID: 8040060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.